Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Treasury Shares (2022 - 2025)

Oramed Pharmaceuticals' Treasury Shares history spans 4 years, with the latest figure at $4.4 million for Q4 2025.

  • For Q4 2025, Treasury Shares changed N/A year-over-year to $4.4 million; the TTM value through Dec 2025 reached $4.4 million, changed N/A, while the annual FY2025 figure was $4.4 million, N/A changed from the prior year.
  • Treasury Shares reached $4.4 million in Q4 2025 per ORMP's latest filing, up from $3.1 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $4.5 million in Q2 2022 to a low of $118522.0 in Q2 2024.
  • Average Treasury Shares over 4 years is $2.3 million, with a median of $1.8 million recorded in 2023.
  • Peak YoY movement for Treasury Shares: grew 17.47% in 2023, then surged 480.22% in 2025.
  • A 4-year view of Treasury Shares shows it stood at $1.6 million in 2022, then rose by 17.47% to $1.8 million in 2023, then plummeted by 70.59% to $539452.0 in 2024, then skyrocketed by 712.58% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Treasury Shares are $4.4 million (Q4 2025), $3.1 million (Q3 2025), and $539452.0 (Q3 2024).